🇺🇸 FDA
Pipeline program

Placebo (10 mM sodium acetate, 9.0% (w/v) sucrose, 0.02% (w/v) polysorbate 20, pH 5.2), EPINEPHRINE , Briquilimab

JSP-CP-011

Phase 2 small_molecule active

Quick answer

Placebo (10 mM sodium acetate, 9.0% (w/v) sucrose, 0.02% (w/v) polysorbate 20, pH 5.2), EPINEPHRINE , Briquilimab for Chronic Spontaneous Urticaria is a Phase 2 program (small_molecule) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Jasper Therapeutics
Indication
Chronic Spontaneous Urticaria
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials